Research programme: diabetes/obesity therapy - Dainippon Sumitomo Pharma/Zoegene

Drug Profile

Research programme: diabetes/obesity therapy - Dainippon Sumitomo Pharma/Zoegene

Alternative Names: Diabetes/obesity therapy research programme - Dainippon/Zoegene

Latest Information Update: 08 Feb 2008

Price : $50

At a glance

  • Originator Dainippon Sumitomo Pharma; Zoegene Corporation
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Diabetes mellitus; Obesity

Most Recent Events

  • 08 Feb 2008 Discontinued for Obesity in Japan (unspecified route)
  • 08 Feb 2008 Discontinued for Diabetes mellitus in Japan (unspecified route)
  • 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top